IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

Contributed by: Business Wire

Logo

Tags

Biotechnology

General Health

Other Health

Health

Pharmaceutical

IMCAS 2026

More Like This

AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community

AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio

IMCAS 2025: Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership

AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education

IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position

ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body

Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS